This clinical trial is focused on studying the treatment of pyogenic vertebral osteomyelitis, a type of bone infection that affects the spine. The study will explore the effectiveness of switching from intravenous (IV) antibiotics to oral antibiotics after one week of IV treatment. The antibiotics being studied include cefuroxime, dicloxacillin, ceftriaxone, amoxicillin, clavulanic acid, cloxacillin, flucloxacillin, ciprofloxacin, clindamycin, vancomycin, linezolid, moxifloxacin, benzylpenicillin, ampicillin, rifampicin, phenoxymethylpenicillin, sulfamethoxazole, trimethoprim, tolu balsam, and meropenem. Some patients will receive a placebo as part of the study.
The purpose of the study is to determine if an early switch to oral antibiotics is as effective as the current standard treatment, which involves two to four weeks of IV antibiotics followed by oral antibiotics. Participants will initially receive IV antibiotics for one week. After this period, they will be randomly assigned to either continue with IV antibiotics or switch to oral antibiotics. The study will monitor the participants for any complications or relapses of the infection over a period of six months after completing the antibiotic treatment.
Throughout the study, various health indicators will be assessed, including the occurrence of any adverse events, the need for additional treatments, and the overall quality of life of the participants. The study aims to provide valuable insights into the potential benefits of transitioning to oral antibiotics earlier in the treatment process for pyogenic vertebral osteomyelitis.
Denmark 